STUDY NUMBER: 2600021 PART 1 COHORT 3

Dear pioneer,

A study to **treat Alzheimer's disease** will soon start at our research centre in Edegem.
Are you interested in participating and giving science a boost?
Hereby we would like to give you an overview of the study: duration of **13 weeks**.

In this cohort, the study medication will be administered **subcutaneously** (under the skin).

In this study, we are investigating the effects of this investigational drug on the body. To measure its concentration in the cerebrospinal fluid (CSF), a sample of CSF will be collected via a **lumbar puncture**. This procedure will be performed under local anesthesia. In this cohort of the study, a lumbar puncture will be performed **twice**.

INCLUSION CRITERIA

- **Last participation in other clinical study (last study medication*):** *no later than 3 months before the administration of the study medication on day 1*
  - Cohort 3 sentinel: no later than 16NOV2026 (16OCT2026 in case of a biological)
  **Be careful: Final study visit of the previous study needs to be performed to be able to participate at screening.*
- Healthy men/women **between** age of 18 and 60 years (inclusive) at screening
- BMI: between 18.5 and 30.0 kg/m²
  - Weight:
    - For woman: between 40.0 and 90.0 kg (inclusive)
    - For man: between 45.0 and 100.0 kg (inclusive)
- Non-smoker, or smoking no more than 10 cigarettes (or equivalent) **per week**. Smoking will not be permitted during your participation in the study.
- Not using any medication, vitamins, or homeopathic substances (in consultation with the physician, it may be possible to continue taking certain medications during the study).
- Contraception:
  - Fertile women:
    - Willing to use an effective method of contraception (e.g., oral contraceptive pill, intrauterine device (IUD), contraceptive injection, contraceptive patch, partner vasectomy, etc.) in combination with an effective barrier method, such as a male condom from Day 1 until at least 5 weeks after administration of the study medication.
    - **OR** Abstinence from heterosexual intercourse
    - **AND** Willing to refrain from donating eggs from Day 1 until at least 10 weeks after administration of the study medication.
    - **AND** must not be pregnant or breastfeeding during participation in the study.
  - Infertile women:
    - postmenopausal (= no menstruation for at least 12 months)
    - **OR** removal of uterus
    - **OR** removal of both ovaries
    - **OR** removal of both fallopian tubes
  - Men: *From day 1 until at least 5 weeks after administration of the study medication*
    - If the partner is of childbearing potential: use of a condom in combination with an effective contraceptive method used by the partner.
    - Use of a condom during every sexual contact.
    - **OR** Abstinence from heterosexual intercourse
    - AND Willing to refrain from donating sperm.

- Prepared to:
  - **Willing to bring your vaccination record (or proof of previous vaccinations) to the screening visit and, if necessary, to receive vaccination against meningococcal disease, pneumococcal disease, and/or Haemophilus influenzae type b (Hib). A maximum of five vaccinations may be administered across three study visits**
  - Undergo an eye examination
  - Undergo lumbar punctures
- You will be asked to follow the restrictions regarding physical activity, consumption of caffeine-, xanthine- and alcoholic products.
- You are not an employee of SGS, nor a family member of an SGS employee who is directly involved in this study.
- You are **not eligible** to participate if:
  - You have a history of infection with HIV, hepatitis B, or hepatitis C.
  - You have systemic lupus erythematosus (SLE) or another autoimmune disease.
  - You have a history of active or latent tuberculosis (TB).
  - You have a severe spinal deformity or have had previous spinal surgery that could make an epidural difficult
  - You have had complications from an epidural in the past
  - You experience frequent headaches and/or migraines, are regularly nauseous, or vomit frequently (more than twice per month).
  - You have received a biologic medication within less than 4 months prior to administration of the study medication.
  - you have participated in a previous cohort of study 2600021

INTEREST IN PARTICIPATING

Registration for this study only indicates your interest and does not obligate you to participate, nor us to include you as a participant.

Thank you in advance for your interest and we hope to welcome you soon for study 2600021-part 1 cohort 3.

SGS CPU